Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:17 PM
Ignite Modification Date:
2025-12-26 @ 10:17 PM
NCT ID:
NCT03223012
Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (SpA) or psoriasis (Pso) according to the treating physician
* Adalimumab was started within 1 month prior to study enrollment
* Adalimumab was introduced based on current clinical practice criteria (i.e., the prescription of adalimumab was clearly separated from the decision to include the participants in this study)
* No prior record of adalimumab treatment
* Adalimumab was administered according to product label
* Naïve or previously experienced with biologic treatment
* Participant is able and willing to provide written authorization to disclose and use personal health information (informed consent), and to agree that data will be collected and provided to AbbVie
AbbVie Care 2.0 Cohort-specific inclusion criteria:
* Initiated the AbbVie care program within the first month after starting adalimumab.
Exclusion Criteria:
* Definitive discontinuation of adalimumab before being proposed to participate in the study
* Participated in any clinical experimental research within the 2 months prior to enrollment
* Pregnant or breastfeeding female participants
* Participant not able or not willing to comply with the requirements of this study protocol.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
99 Years
Study:
NCT03223012
Study Brief:
Protocol Section:
NCT03223012